期刊文献+

选择性COX-2抑制剂的安全性评估 被引量:9

Safety Assessment of Selective COX-2 Inhibitors
下载PDF
导出
摘要 概述选择性 COX-2抑制剂的临床特点及其胃肠道、心血管和肾脏的安全性,分析药物产生非胃肠道不良反应的机制,为此类药物临床合理应用提供依据。 Summarize the clinical characteristics of selective COX-2 inhibitors, and the gastrointestinal, cardiovascular and renal toxicity associated with these drugs. Analyze the mechanism of non-gastrointestinal adverse reactions of selective COX-2 inhibitors and provid the evidence for drug rational use.
出处 《中国药物警戒》 2005年第1期16-20,共5页 Chinese Journal of Pharmacovigilance
关键词 COX-2抑制剂 安全性 罗非昔布 塞来昔布 COX-2 Inhibitors Safety Rofecoxib Celecoxib
  • 相关文献

参考文献14

  • 1[1]Robert W.Mcmurray,Kenneth J.Hardy.Cox-2 inhibitors:today and tomorrow[J].Am J Med Sci 2002,323(4):181-189. 被引量:1
  • 2[2]Bombardier C,Laine L,Reicin A,etal.Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis:VIGOR Study Group[J].N Engl J Med 2000,343(21):1520-1528. 被引量:1
  • 3[3]Silverstein FE,Faich G,Goldstein JL,et al.Gastrointestinal toxicity with celecoxib vs NSAIDs for osteoarthritis and rheumatoid arthritis:the CLASS study:a randomized controlled trial:Celecoxib Long-term Arthritis Safety Study[J].JAMA 2000,284(10):1247-1255. 被引量:1
  • 4黄世杰.塞来昔布不比双氯芬酸好[J].国外医学(药学分册),2003,30(4):252-253. 被引量:2
  • 5[5]Laurence G.Howes,Henry Krum.Selective Cyclooxygenase-2 inhibitors and myocardial infarction[J].Drug safety,2002,25(12):829-835. 被引量:1
  • 6[6]Matthew R.,Rhoda S.S.,Alise R.,Selective COX-2 inhibition and cardiovascular effects:a review of the rofecoxib development program[J].Am.Heart J.2003,146:591-604. 被引量:1
  • 7[8]D.Craig Brater.Renal effects of cyclooxygyenase-2-selective inhibitors[J].J Pain Symptom Manage.2002,23:S15-20. 被引量:1
  • 8[9]Suzanne.K,Swan,David W.Rudy.Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet[J].ANN intern Med.2000,133:1-9. 被引量:1
  • 9[10]Syed R.Ahmad,Cindy Kortepeter,Allen Brinker,Renal failure associated with the use of celecoxib and rofecoxib[J].Drug safety.2002,25(7):537-544. 被引量:1
  • 10[11]CPMP.Overall summary of the scientific evaluation of medicinal products containing celecoxib,etoricoxib,parecoxib,rofecoxib and valdecoxib[S]. 被引量:1

共引文献1

同被引文献115

引证文献9

二级引证文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部